株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:世界の脂質異常症の疫学的予測

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 262489
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
EpiCast Report:世界の脂質異常症の疫学的予測 EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023
出版日: 2014年10月15日 ページ情報: 英文 94 Pages
概要

世界の主要8ヶ国における脂質異常症の有病者数は、2013年の5億7241万8492人から、2023年には6億8590万5635人まで、年平均(CAGR)1.99%で増加すると予想されています。ドイツを除く全ての国で、脂質異常症の有病者数は増加傾向にあります。また2023年には、家族性高コレステロール血症(FH)の有病者数の有病者数は436万5831人、高LDLコレステロール血症は4億1173万7455人、超高トリグリセリド血症(TG)は1274万6492人に達する見通しです。

当レポートでは、世界の主要8ヶ国(米国・ドイツ・フランス・イタリア・スペイン・英国・日本・中国)における脂質異常症の発症状況と今後の見通しについて分析し、脂質異常症の特徴や、各国での詳細状況、今後10年間の発症件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界各国・地域の動向
    • 米国
    • 欧州主要5ヶ国
    • アジア
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 脂質異常症の疫学的予測(今後10年間分)
    • 脂質異常症の有病者総数
    • 年齢層別の有病者数
    • 男女別の有病者数
    • 年齢調整済みの有病者総数
  • 家族性高コレステロール血症の疫学的予測(今後10年間分)
    • 家族性高コレステロール血症の有病者総数
  • 高LDLコレステロール血症の疫学的予測(今後10年間分)
    • 高LDLコレステロール血症の有病者総数
    • 年齢層別の有病者数
    • 男女別の有病者数
    • 年齢調整済みの有病者総数
  • 超高トリグリセリド血症(TG)の疫学的予測(今後10年間分)
    • 超高トリグリセリド血症の有病者総数
    • 年齢層別の有病者数
    • 男女別の有病者数
    • 年齢調整済みの有病者総数
  • 議論
    • 疫学的傾向に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER004-14

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.

GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally, GlobalData epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.

GlobalData epidemiologists used comprehensive, country-specific data from population based national health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). For all the 8MM, the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were segmented by age and sex, which facilitates an understanding of the distribution of disease within the population, and informs strategies to improve the management of disease.

Scope

  • The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets.
  • The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
  • Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Asia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Dyslipidemia (2013-2023)
    • 3.5.1. Total Prevalent Cases of Dyslipidemia
    • 3.5.2. Age-Specific Total Prevalent Cases of Dyslipidemia
    • 3.5.3. Sex-Specific Total Prevalent Cases of Dyslipidemia
    • 3.5.4. Age-Standardized Total Prevalence of Dyslipidemia
  • 3.6. Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023)
    • 3.6.1. Total Prevalent Cases of Familial Hypercholesterolemia
  • 3.7. Epidemiological Forecast for Increased LDLc (2013-2023)
    • 3.7.1. Total Prevalent Cases of Increased LDLc
    • 3.7.2. Age-Specific Total Prevalent Cases of Increased LDLc
    • 3.7.3. Sex-Specific Total Prevalent Cases of Increased LDLc
    • 3.7.4. Age-Standardized Total Prevalence of Increased LDLc
  • 3.8. Epidemiological Forecast for Very High TG (≥500mg/dL) (2013-2023)
    • 3.8.1. Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.2. Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.3. Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 3.8.4. Age-Standardized Total Prevalence of Very High TG (≥500mg/dL)
  • 3.9. Discussion
    • 3.9.1. Epidemiological Forecast Insight
    • 3.9.2. Limitations of the Analysis
    • 3.9.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Dyslipidemia
  • Table 2: Overview of the Total Prevalence of Low HDLc in the 5EU
  • Table 3: NCEP-ATP III Classification of LDLc, TG, and HDLc
  • Table 4: Simon Broome Diagnostic Criteria for FH
  • Table 5: LDLc Based Definition of FH
  • Table 6: Sources of Total Prevalence Data for FH in the 8MM
  • Table 7: Sources of Total Prevalence Data for Increased LDLc in the 8MM
  • Table 8: Sources of Total Prevalence Data for High TG (≥200mg/dL) in the 8MM
  • Table 9: Sources of Total Prevalence Data for Very High TG (≥500mg/dL) in the 8MM
  • Table 10: Sources of Total Prevalence Data for Low HDLc in the 8MM
  • Table 11: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia
  • Table 12: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 13: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013
  • Table 14: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N (Row %), 2013
  • Table 15: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 16: 8MM, Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 17: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, N (Row %), 2013
  • Table 18: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N (Row %), 2013
  • Table 19: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 20: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, N (Row %), 2013
  • Table 21: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 8MM, Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N, 2013
  • Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDLc (≥115mg/dL to ≥160mg/dL)* (%), Ages ≥20 Years, by Sex, 2013
  • Figure 10: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N, 2013
  • Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (≥500mg/dL) (%), Ages ≥20 Years, by Sex, 2013
Back to Top